Chapter 20: Purine and Urate Metabolism

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back.

We are so excited to have you with us today.

For this deep dive, we are basically acting as your personal tutors.

Right, just you and us sitting down, hitting the books and getting you completely confident with this material.

Exactly.

Our mission today is Mastering Chapter 20 of Clinical Biochemistry and Metabolic Medicine, the 8th edition.

We are looking specifically at Purine and Urate Metabolism.

Which is a huge topic.

It is.

We're going to walk you through the exact sequence of the chapter, breaking down these massive physiological pathways, tracing the feedback loops, tackling a real clinical case, and finally exploring the diagnostic algorithm.

So you know exactly what to do when you see this on the wards.

And framing this right from the start is so important for you as a college student stepping into clinical biochemistry.

I mean, memorizing metabolic pathways can sometimes feel a bit abstract.

Like you're just staring at a complex subway map.

Yeah, exactly.

But understanding these normal biochemical principles is the absolute key to unlocking pathophysiology.

Once you truly grasp how the normal system is supposed to work, the abnormal makes perfect sense.

Which in turn makes sense of your laboratory findings.

Right, and that directly dictates how you manage your patient.

It isn't just rote memorization.

It is all fundamentally connected.

I completely agree.

And to hook you right away, the text points out this fascinating evolutionary quirk.

We humans actually lack a specific enzyme called uricase.

Which is pretty rare for mammals.

Yeah, most other mammals have this enzyme, and they use it to break urate down into a highly water -soluble substance called allantoin, which is easily flushed out.

But we simply don't have it.

We don't.

That leaves us with much higher baseline uric acid levels compared to other mammals, giving us a very unique vulnerability to gout and progressive renal damage.

Okay, let's unpack this.

Starting with the biochemical blueprint of normal purine metabolism.

Before we even talk about disease, what exactly are we building here?

Let's start with the absolute basics.

What are purines?

The main ones we are concerned with in clinical biochemistry are adenine and guanine.

You probably recognize those names.

You definitely should.

They are the essential building blocks, the structural constituents of DNA and RNA.

Every cell in your body needs them.

Now, let's look at your body's daily urate math.

About two -thirds of the body's urate, which comes out to roughly three to four millimoles per day, is produced endogenously.

Meaning it's synthesized right there within your body's own cells.

Exactly.

The remaining one -third, about one to two millimoles per day, comes from exogenous dietary purines.

This is usually from cell -rich foods like red meat or seafood,

foods packed with DNA and RNA that your digestive system breaks down.

Wait, so if we don't have the uricase enzyme to easily break it all down, does that mean every single purine we eat, plus everything we make internally, eventually has to be meticulously filtered out by the kidneys?

That seems like a massive daily workload.

It is a significant workload, which is exactly why the regulatory systems have to be so tightly controlled.

If we look at how the body builds those endogenous purines, it's essentially a highly regulated manufacturing assembly line.

The very first step in purine synthesis is taking a molecule called pyrophosphate and condensing it with phosphorabose.

Together, they form a foundation molecule called

phosphorabosyl pyrophosphate, or PRPP for short.

And once we have that PRPP foundation, the second step on the assembly line is the one you really need to highlight in your notes.

This is the rate -limiting step.

Super important.

The amino group from glutamine is added to that PRPP molecule by a specific enzyme called

amitophosphorabosyl transferase.

The result is phosphorabogologen.

You have to remember this specific enzyme because it is subject to an essential negative feedback loop.

Think of this negative feedback loop like a thermostat in your house.

As purine nucleotides build up in the body and reach sufficient levels, they physically bind to and inhibit that enzyme.

The amitophosphorabosyl transferase.

Right.

This signals the assembly line to slow down further production.

If that control mechanism is impaired or broken, synthesis just runs completely unchecked.

The furnace never turns off.

And that unchecked production is a primary driver of primary gout.

Precisely.

So, assuming the thermostat is working, let's keep building the molecule.

Next, the amino acid glycine is added to the mix.

The text specifically highlights that glycine provides crucial atoms to build out the physical structure of the purine ring.

And through a few more metabolic steps, we eventually form those finished purine

nucleotides.

Now, to bring this back to the clinic, there is a major therapeutic correlation you need to know.

Certain cytotoxic drugs, like those used in chemotherapy, are designed to intentionally inhibit these specific early stages of the synthesis pathway.

Right.

Because if a cancer cell is rapidly dividing, it desperately needs new DNA.

If you use a drug to block purine synthesis, you starve the cell of adenine and guanine, you prevent DNA formation, and effectively stop cell growth.

It's an elegant, if harsh, way to target rapidly dividing cells.

Here's where it gets really interesting.

What actually happens to these purines once they've done their job?

Cells die, DNA is degraded, where does all that material go?

It has two main fates, oxidation or salvage.

Let's look at oxidation first, which is the breakdown pathway leading to disposal.

Adenine is oxidized into a compound called hypoxanthine, which is then oxidized into xanthine.

And guanine also breaks down to form xanthine.

Exactly.

Finally, the xanthine is oxidized one last time to form urate.

Crucially, this final oxidation process happens primarily in the liver and is catalyzed by a highly specific enzyme called xanthine oxidase.

Make a giant mental star next to xanthine oxidase.

Yes.

Burn it into your mind, because it's a massive pharmacological target we will be discussing when we get to patient management.

Got it.

So that's the disposal route.

But earlier you mentioned a salvage pathway.

Is the body actually recycling these molecules?

It is, and it's incredibly efficient.

Instead of breaking all these valuable purines down in urate to be thrown away, specialized enzymes step in and rescue them.

The big one to know is HGPRT, along with another called APRT.

And what do they do?

These enzymes grab xanthine, hypoxanthine and guanine off the disposal line and recycle them right back into usable purine nucleotides.

It saves the body the immense energetic cost of building new purines from scratch.

That recycling program is amazing, but inevitably some urate is formed and has to leave the body.

So let's talk about excretion.

Urate is filtered out of the blood by the glomeruli in the kidneys.

But surprisingly, most of it is actually reabsorbed back into the blood in the proximal tubules.

Right, which sounds counterproductive.

It does.

More than 80 % of the urate that ultimately ends up in your urine actually comes from active secretion later on in the distal tubules.

And there's a quick demographic note from the chapter here that is highly relevant.

Males inherently excrete slightly less urate than females do, which structurally predisposes them to hyperuricamia.

And as clinicians, we can actually modify that renal excretion.

We have uricoceric drugs like probenicid or sulfamperazone.

These drugs actively block that tubular reabsorption we just talked about, which forces more urate to stain the urine and leave the body.

On the flip side, there are substances that do the opposite.

Yes.

Lactic acid, ketones and thiazide diuretics actually inhibit the distal tubular secretion, effectively trapping urate inside the body.

Ultimately, under normal conditions, about 75 % of urate leaves the body via the urine.

The remaining 25 % passes into the intestinal tract, where it gets broken down by intestinal bacteria in a process known as urocolysis.

So we've got this incredibly efficient recycling program and a multi -step filtration system in the kidneys.

But no system is perfect.

What actually happens when the body's urate math stops adding up?

That brings us to hyperuricamia.

Right.

The text broadly categorizes the causes into two distinct mechanical failures.

You either have overproducers, meaning there is increased internal synthesis, massive dietary intake or rapid tissue broke down.

Or you have under excretors, where the kidneys just aren't clearing it fast enough.

To truly understand the clinical consequences of hyperuricamia, we have to look at how urate behaves chemically.

Urate is a very poorly soluble molecule.

Think of urate as a molecule that usually carries a negative electrical charge in normal neutral blood plasma.

That charge acts like a magnet, grabbing onto sodium, which keeps it somewhat dissolved.

But when the environment gets acidic?

Like in your urine when pH falls below about 6.

Exactly.

It loses that negative charge.

It becomes neutral uric acid.

And suddenly it clumps together, much like unmixed powder in a cold glass of water.

It precipitates out of the solution, forming solid renal calculi, commonly known as kidney stones.

And that exact physical precipitation is what triggers the classic,

agonizing vicious cycle of an acute gout attack.

Let's paint the picture of what is happening in a patient's joint.

Urate crystallizes in the synovial fluid, very often in the joints of the feet, like the big toe.

The body's immune system sees these sharp crystals and launches a massive inflammatory response.

White blood cells swarm the area to essentially eat and destroy the crystals.

But as those white blood cells work over time, their metabolism produces lactic acid.

And that lactic acid drops the local pH right there inside the joint.

And just like we saw in the acidic urine, that lower pH in the joint converts the surrounding urate into the even less soluble uric acid.

So you get more precipitation, more crystals forming.

Which causes more white blood cells to arrive, creating more inflammation, and more lactic acid.

It is a relentless, incredibly painful feedback loop.

And here is a massive clinical pearl for you to take to your ward rotations.

During one of these acute painful gout attacks, the patient's plasma urate concentration, the actual level in their blood, is usually totally normal.

Which trips up a lot of students.

It does.

The attack is being driven by those local acidic factors and the localized immune response in that specific joint, not necessarily by a spike in the overall blood concentration at that exact moment.

Now, over years of chronic hyperruricamia, this precipitation leads to gouty tophi.

Those are visible, nodular deposits of solid urate in subcutaneous tissues, especially on the ears.

Or in bursa, like the elbow or the kneecap.

Clinically, the threshold number to burn into your memory is 600 micromoles per liter.

Even if a patient is completely asymptomatic and has never had a gout attack, if their urate is consistently above 600, treatment is generally recommended to prevent silent, progressive renal damage.

Let's dig into the specific causes, starting with primary hyperruricamia.

Looking at the demographics,

primary cases are actually very rare in children and premenopausal women.

For both sexes, urate levels naturally rise at puberty, but the jump is much, much higher in males.

Women generally catch up and become much more prone to hyperruricamia and gout later in life, specifically in the postmenopausal period.

And if someone has a baseline tendency toward gout,

certain precipitating factors will absolutely set it off.

A high -meat diet provides a huge exogenous load of purines.

Thiazide diuretics, as we mentioned earlier, actively reduce renal excretion.

And alcohol is a classic major trigger.

Why does alcohol trigger it so reliably?

Is it just the purines in beer?

It's actually deeper than that.

It's about the biochemistry of alcohol metabolism.

Processing alcohol in the liver drastically increases lactic acid production in the body.

And as we just learned with the kidney tubules, elevated lactic acid actively competes with and inhibits the renal secretion of urate.

The alcohol is essentially telling the kidneys to hold on to the urate.

Wow, that makes perfect sense.

If we look at the specific genetic or biochemical defects behind these primary hyperruricamia cases, about 25 % of them involve an overactive amitophosphorbasol transferase.

Remember that rate -limiting enzyme from step two of the assembly line?

Right, if the thermostat is broken and it's overactive, you get massive overproduction.

Other primary cases simply have an unexplained idiopathic reduced tubular secretion.

The text also notes a very rare autosomal dominant condition called familial juvenile gouty nephropathy, which leads to progressive severe renal failure.

What's fascinating here is when we look at the exceedingly rare juvenile causes, specifically a condition called Lesch -Nihan syndrome.

This is an X -linked recessive disorder, meaning it almost exclusively affects young male children.

These patients are born completely lacking that crucial salvage enzyme we discussed earlier.

HGPRT.

Right, because their bodies cannot recycle hypoxantine and guanine back into useful purine nucleotides, every single purine molecule gets shunted down the disposal line into oxidation.

So the recycling center is closed, and the incinerator is running at maximum capacity.

Precisely.

The result is massive, severe hyperuricamia from a very young age, accompanied by devastating neurological symptoms.

Profound mental deficiency, spastic paraplegia, and a hallmark tragic tendency toward aggressive self -mutilation.

It is a stark reminder of how critical these single enzymes are.

There is also a less severe partial deficiency of HGPRT, known as Kelly -Siegmiller syndrome, in cases driven by an inherent overactivity of PRPP synthase.

Let's move from those primary inherited defects into secondary hyperuricamia, where the elevated urate is a direct consequence of another disease or condition.

We'll start with conditions causing increased nucleic acid turnover.

This happens whenever cells are rapidly dividing or rapidly breaking down.

You see it heavily in malignancies like leukemias or lymphomas, in severe psoriasis where skin cell turnover is hyperactive after massive physical trauma, or even during prolonged starvation and kigoacidosis.

Let's apply this concept with a clinical case directly from the chapter.

Case 1 describes a 62 -year -old man who just received heavy chemotherapy for non -Hodgkin's lymphoma.

The oncologist sends over his post -chemo blood work.

Okay, let's hear the labs.

His sodium is 137, which is normal, but his potassium is elevated at 5 .6.

His estimated GFR is 48, indicating significantly impaired kidney function.

His phosphate is sky -high at 3 .17.

And his plasma urate is an absolutely massive 740 micromoles per liter.

A urate level of 740.

That is astronomical.

So what does this all mean?

What is happening in this guy's body?

In a clinical setting, if you see numbers like that post -chemo, alarm bells should be ringing for tumor lysis syndrome.

The chemotherapy did its job almost too well.

It rapidly destroyed a massive systemic burden of tumor cells, all at exactly the same time.

When millions of those cancer cells burst open, they dumped their entire intracellular contents directly into the bloodstream.

Right.

That means a sudden flood of intracellular potassium causing hyperkalemia, a flood of phosphate causing hyperphosphatemia, and a massive dump of purine metabolites.

The liver rapidly converts those purines to urate, causing that severe hyperruricamia.

This massive urate load can instantly trystallize in the renal tubules and cause acute oliguric renal dysfunction, meaning the kidneys just stop making urine.

This is exactly why aggressive intravenous hydration and pre -treatment with allopurinol are absolutely critical protocols before initiating these chemotherapy regimens.

We also have secondary hyperruricamia caused by reduced excretion.

We've mentioned thiazide diuretics holding urate back, but this also includes low -dose salicylates and broader renal glomerular dysfunction where the kidneys are just failing overall.

The text gives a fantastic diagnostic trick here for when you are on the wards.

If a patient has known kidney disease and they also have hyperruricamia, how do you know which caused which?

Did the bad kidneys cause the high urate or did the high urate damage the kidneys?

It's a classic chicken or egg scenario.

Exactly.

And the trick is comparing the urate to creatinine concentration ratio in a spot urine If the ratio is less than 0 .7, it means the primary renal impairment came first, and the failing kidneys are the cause of the high urate backing up.

But if the ratio is greater than 0 .7, it suggests urate nephropathy, meaning the extreme high urate levels actually came first and caused the kidney damage.

We also see secondary hyperruricamia from combined causes, meaning the patient suffers from both overproduction and under excretion simultaneously.

This includes high alcohol intake,

extreme severe exercise, and metabolic syndrome or type 2 diabetes, which is heavily driven by insulin resistance.

But I want you to pay special attention to a glycogen storage disease called von Gierke's disease or glucose 6 phosphatase deficiency.

Right, because this creates a massive biochemical traffic jam.

Exactly.

Because these patients lack the specific enzyme required to convert glucose 6 phosphate into free glucose, that G6P gets trapped inside the liver cells.

It can't get out, so it has to be shunted down alternative metabolic side roads.

First, it diverts heavily into the pentose phosphate pathway, which generates excessive ribose phosphate.

That massively accelerates the very first step of purine synthesis.

Simultaneously, the trapped G6P diverts down into glycolysis, creating vast excess amounts of lactic acid.

And as we know, lactic acid blocks the renal excretion of urate.

So you have a perfect storm.

Massive overproduction meeting blocked excretion.

Okay, so you've investigated the pathway as you've diagnosed the patient.

Let's talk about the final step.

Treatment and patient management.

For an acute raging attack of gout, the primary goal is shutting down that vicious inflammatory cycle.

You use NSAIDs, sometimes corticosteroids, or a specific drug called colchicine.

It's incredibly important to understand the mechanism here.

Colchicine works by inhibiting neutrophil activation.

It physically stops the white blood cells from attacking the crystals and releasing lactic acid.

But it does not actually lower the urate levels in the blood.

Right.

For long -term management to actually lower the urate burden, we target the production side.

Allopurinol is the classic gold standard drug here.

Structurally, allopurinol looks very, very similar to hypoxanthine.

Because of that structural mimicry, it acts as a competitive inhibitor of our old friend xanthine oxidase.

It physically sits in the enzyme's active site, blocking it from oxidizing hypoxanthine and xanthine into urate.

But I must strongly warn you.

Never, ever start a patient on allopurinol during an acute gout attack.

Why is that?

If their urate is causing the problem, shouldn't we lower it immediately?

It seems counterintuitive.

But rapidly shifting the plasma urate levels can actually mobilize existing microcrystals in the joints, triggering a new immune response and dramatically worsening the current attack.

You must wait a few weeks until the acute inflammation completely subsides, and then initiate the allopurinol slowly, usually under the protective cover of a low -dose NSAA.

If a patient simply cannot tolerate allopurinol, febuxostat is a great non -competitive inhibitor alternative.

Or, as we discussed earlier, you can focus on the kidney side and increase renal excretion with urochocert drugs like probenacid, provided their underlying kidney function is still intact.

Let's tie all of this diagnostic work together.

The chapter outlines a comprehensive investigation algorithm.

When you have a patient with hyperuricamia, don't just blindly order tests.

Think of it in three distinct phases.

First, look outward at their environment.

Take a detailed drug and poison history.

Are they on thiazide diuretics?

Are they exposed to lead, which damages the tubules?

Are they drinking heavily?

Second, look at their baseline hardware.

Check the family history for hereditary forms, and check their kidney function with plasma urea, creatinine, and use that spot urine ratio trick.

And finally, look at their internal metabolic state.

Are there high cell turnover conditions like undocumented tumors or severe psoriasis?

Is there evidence of metabolic acidosis or metabolic syndrome?

If you're still stuck, you consider a 24 -hour urine analysis on a strict low -purine diet to definitively classify them as an overproducer or under -excreter.

And only then do you start hunting for those extremely rare enzyme defects like Leschneihan or von Gierkes.

Following that structured logic will save you a lot of time.

Now, a quick caveat.

You will inevitably encounter a patient presenting with a hot, swollen joint that looks exactly like an acute gout attack, but it is actually a condition called pseudo -gout.

Pseudo -gout is not a purine disorder at all.

Instead of urate, calcium pyrophosphate crystals are what precipitate in the joint cavity.

The diagnostic hallmarks are very clear if you know what to look for.

The patient's plasma urate concentration is completely normal.

If you aspirate the joint fluid and look at the crystals under a polarizing microscope, they show positive birefringence, unlike true urate gout, which is negative.

And radiologically, you will see a distinct calcification of the articular cartilage, known as chondrocalcinosis.

Pseudo -gout is associated with entirely different underlying metabolic conditions like hyperparathyroidism, hemochromatosis, and Wilson's disease.

Wrapping up the textbook content, we have to briefly mention the opposite end of the spectrum,

hyporechaemia, or abnormally low plasma urate.

It's quite rare, and most commonly, it's just an iatrogenic result of over -treating a gout patient with too much allopurinol or probenicid.

But it can occur naturally if there is severe proximal renal tubular damage, like in Van Kony syndrome, where the kidney just leaks it all out.

It can also be seen transiently during pregnancy, in SIADH, or in type 1 diabetes mellitus.

There's also a very rare autosomal recessive inborn error called zenthenuria, where the patient is naturally genetically deficient in liver xanthine oxidase.

Because they lack the enzyme,

purine breakdown just stops at the xanthine and hypoxanthine stage, leading to exceptionally low urate levels.

The irony here is that the massive excess of xanthine can actually precipitate in the acidic urine and cause rare xanthine kidney stones.

You might logically wonder if giving a Why doesn't that drug cause xanthine stones too?

It's a great question.

It's likely because allopurinol also has a secondary upstream effect of inhibiting overall de novo purine synthesis.

It slows the whole assembly line down, preventing the xanthine from ever reaching those dangerous stone forming concentrations.

And there you have it.

You have officially mastered Chapter 20.

We've gone all the way from the basic synthesis of a purine ring and those crucial negative feedback thermostats through the vicious acidic cycle of a gout attack, survived the intense tumor lysis syndrome clinical case, and stepped logically through the diagnostic and treatment algorithms.

You are absolutely going to crush this material on your exams and when you're taking care of patients on the wards.

If we connect this to the bigger picture, let's return to that fascinating evolutionary trait mentioned at the very beginning of our session.

We humans entirely lost the uricase enzyme, leaving us with persistently high uric acid levels and the agonizing risk of gout.

Why would evolution allow a mutation that causes us such severe joint pain and potential kidney damage to survive and propagate?

It's a great question.

Well, it turns out uric acid is actually a highly potent antioxidant in the blood.

By losing the ability to break it down, early primates may have gained a massive built -in defense mechanism against oxidative stress and cellular aging.

It potentially gave us a vital survival advantage in harsh environments.

It really makes you look at the human body differently.

Every strange vulnerability or quirk we have might just be the ghost of an ancient survival mechanism that kept our ancestors alive.

It is definitely something to think about the next time you're looking at a basic metabolic panel and see that urate level.

On behalf of the last minute lecture team, thank you so much for studying with us today.

Keep up the great work and we'll see you for the next deep dive.